Combinations of WFC with mucosal-protective agents (WFC + MPAs), prokinetics (WFC + prokinetics), and H. pylori eradication therapy (WFC + HET) consistently outperformed monotherapies in improving clinical efficacy, regulating gastrointestinal hormones (gastrin and motilin), and relieving major symptoms such as abdominal pain, distension, and acid reflux. Here, MLN is linked to gastroesophageal reflux disease.